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Abstract
Genome-wide association studies (GWAS) have revealed that the genetic contribution to certain complex diseases is well-
described by Fisher’s infinitesimal model in which a vast number of polymorphisms each confer a small effect. Under Fisher’s 
model, variants have additive effects both across loci and within loci. However, the latter assumption is at odds with the com-
mon observation of dominant or recessive rare alleles responsible for monogenic disorders. Here, we searched for evidence 
of non-additive (dominant or recessive) effects for GWAS variants known to confer susceptibility to the highly heritable 
quantitative trait, refractive error. Of 146 GWAS variants examined in a discovery sample of 228,423 individuals whose 
refractive error phenotype was inferred from their age-of-onset of spectacle wear, only 8 had even nominal evidence (p < 0.05) 
of non-additive effects. In a replication sample of 73,577 individuals who underwent direct assessment of refractive error, 1 
of these 8 variants had robust independent evidence of non-additive effects (rs7829127 within ZMAT4, p = 4.76E−05) while a 
further 2 had suggestive evidence (rs35337422 in RD3L, p = 7.21E−03 and rs12193446 in LAMA2, p = 2.57E−02). Account-
ing for non-additive effects had minimal impact on the accuracy of a polygenic risk score for refractive error (R2 = 6.04% 
vs. 6.01%). Our findings demonstrate that very few GWAS variants for refractive error show evidence of a departure from 
an additive mode of action and that accounting for non-additive risk variants offers little scope to improve the accuracy of 
polygenic risk scores for myopia.
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Introduction
Myopia (nearsightedness) is an increasingly common disor-
der usually caused by excessive expansion and elongation of 
the eye during childhood (Morgan et al. 2012). The preva-
lence of myopia varies widely across geographical regions, 
peaking in urbanized areas of East and Southeast Asia and 
lowest in rural areas of countries with poorly developed 
education systems (Mountjoy et al. 2018). The expansion in 
size of myopic eyes is accompanied by thinning and stretch-
ing of the retina, choroid and sclera, which is associated 
with a heightened risk of sight-threatening impairments such 
as myopic maculopathy, retinal detachment and glaucoma 
(Ohno-Matsui 2016). The increasing prevalence of the con-
dition coupled with its associated pathological complica-
tions has resulted in myopia becoming a leading cause of 
blindness and visual impairment, especially in parts of Asia 
(Fricke et al. 2018).
Refractive error is a continuous trait quantifying how 
accurately the eye focuses an image of distant objects 
on the retina. Myopia represents the negative arm of the 
refractive error distribution and hyperopia (farsighted-
ness) the positive arm. Refractive error is highly herit-
able: Twin studies have reported a heritability in the 
range H2 = 0.75–0.91 (Sanfilippo et  al. 2010), family-
based studies h2 = 0.15–0.70 (Sanfilippo et al. 2010), and 
‘SNP-heritability’ (inter-individual variance in refractive 
error explained by commonly occurring genetic variants) 
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hSNP2 = 0.35–0.39% (Guggenheim et al. 2015; Shah et al. 
2018). Genome-wide association studies (GWAS) have 
identified approximately 150 genetic variants associated 
with refractive error, which together explain approximately 
4–6% of the inter-individual variation (Kiefer et al. 2013; 
Verhoeven et al. 2013; Tedja et al. 2018). Environmental 
and lifestyle-related risk factors such as time spent out-
doors in childhood, years spent in education, birth order 
and time spent performing near vision tasks have been 
reproducibly associated with refractive error and myopia 
(Enthoven et al. 2019).
The known GWAS variants associated with a refrac-
tive error each have small effects when considered on a 
population-wide basis, i.e. each explains < 0.5% of the 
inter-individual variation [effects appear to be larger 
in certain individuals than others, most likely due to 
gene–environment or gene–gene interactions (Pozarickij 
et al. 2019)]. Current projections suggest that thousands 
of loci are associated with the trait (Tedja et al. 2019). 
In this regard, the genetic contribution to refractive error 
conforms closely to Fisher’s infinitesimal polygenic 
model (Lynch and Walsh 1997). One of the expectations 
or assumptions of an infinitesimal model is that the effects 
of individual genetic variants combine additively to deter-
mine the genetic contribution to the phenotype. Thus, for 
example, in predicting refractive error using a polygenic 
risk score (Fan et al. 2016; Enthoven et al. 2019; Ghor-
bani Mojarrad et  al. 2020), researchers sum the effect 
expected for each allele of each variant according to two 
implicit assumptions: (1) there are no gene–gene interac-
tion effects (epistasis), and (2) there are no allele-allele 
interaction effects (dominance). Dominant and recessive 
inheritance of monogenic traits are well known examples 
of non-additive allele-allele interaction effects. However, 
tests for dominance are rarely performed in association 
studies of polygenic human traits. To date, the evidence 
argues against widespread non-additive effects for most 
human complex traits (Zhu et al. 2015) although examples 
of common variants with strong evidence of non-additivity 
exist (Lenz et al. 2015; Wood et al. 2016; Plotnikov et al. 
2019). If non-additive allelic effects are widespread in 
variants conferring susceptibility to refractive error, then 
accounting for them should improve the accuracy of poly-
genic risk scores.
Genetic variants with non-additive effects can be 
detected in a conventional GWAS analysis that assumes 
variants act additively, albeit with reduced statistical 
power compared to an analysis in which the correct model 
is specified (Sham and Purcell 2014; Dizier et al. 2017). 
Therefore, currently identified GWAS variants could, 
in fact, have dominant or recessive effects despite the 
assumption that they act additively. The aim of this study 
was to screen the known variants associated with refrac-
tive error for non-additivity (dominance).
Materials and methods
UK Biobank study sample
The UK Biobank is a longitudinal cohort study designed to 
investigate the health and well-being of older adults living 
in the UK (Sudlow et al. 2015). The study recruited over 
500,000 adults aged 37–73 years old during the period 
2006–2010. Ethical approval was obtained from the 
National Health Service National Research Ethics Service 
(Ref 11/NW/0382) and all participants provided written 
informed consent. Detailed information on a wide range of 
phenotypes was collected through questionnaire responses 
and physical assessments carried out at a research clinic. 
High-density single nucleotide polymorphism (SNP) gen-
otyping was carried out on DNA extracted from blood 
samples. An ocular assessment that included non-cyclople-
gic autorefraction was introduced towards the end of the 
recruitment period, which 23% of participants underwent. 
Descriptions of the ophthalmic assessment and refractive 
error findings have been published previously (Cumber-
land et al. 2015; Chua et al. 2019). Details of the genotyp-
ing, imputation and quality control procedures have been 
reported by Bycroft et al. (2018).
Discovery and replication sample
Separate groups of UK Biobank participants were selected 
as the discovery and replication samples, according to the 
flow diagram in Fig. 1. The replication sample comprised 
of n = 73,577 individuals classified as having White Brit-
ish ancestry by Bycroft et al. (2018) who underwent direct 
assessment of refractive error by non-cycloplegic autorefrac-
tion (Cumberland et al. 2015) and who did not self-report 
or have a known history of any eye disorder or pathology 
that may have affected their refractive error, as described 
(Pozarickij et al. 2019). The discovery sample comprised 
of n = 228,423 individuals of White British ancestry who 
had a known age-of-onset of spectacle wear (AOSW) and 
who either did not undergo autorefraction or who reported 
or had a known history of eye pathology. All n = 302,000 
participants were unrelated, where this was defined as a 
pairwise kinship less than that of third-degree relatives 
(Bycroft et al. 2018). As with previous large-scale studies 
of refractive error genetics (Verhoeven et al. 2013; Tedja 
et al. 2018, 2019), we made the assumption that refractive 
error is largely stable in adulthood.
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Genetic variants associated with refractive error
We investigated 146 genetic variants with strong evidence 
of association with refractive error (Pozarickij et al. 2019). 
Specifically, these were variants identified at the threshold 
p < 5 × 10–8 in a GWAS mega-analysis reported by Tedja 
et al. (2018) that combined a meta-analysis of GWAS for 
refractive error in a total sample of n = 56,127 participants 
from the CREAM consortium and a meta-analysis of GWAS 
for age-of-onset of myopia diagnosis in a total sample of 
n = 104,293 research-consenting customers from 23andMe 
Inc. We restricted attention to variants that were replicated 
in an independent sample of n = 95,505 individuals from UK 
Biobank by Tedja et al. (2018) and that had a minor allele 
frequency (MAF) sufficient to expect there to be at least 50 
participants homozygous for the minor allele in the replica-
tion sample (MAF > 0.03). Imputed genotype data were con-
verted to ‘hard calls’ using the command hard-call-threshold 
0.1 in PLINK 1.9 (Chang et al. 2015).
Classification of individuals in the discovery sample 
as myopic or non‑myopic
Supplementary Note 1 describes (i) how the relationship 
between refractive error and AOSW was modelled for par-
ticipants in the replication cohort who had data available 
for both phenotypes, and (ii) how this model was utilised 
to infer whether participants in the discovery sample were 
myopic or non-myopic.
Fig. 1  Selection of UK Biobank 
participants for discovery and 
replication sample
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In brief, a logistic regression model was derived for par-
ticipants in the replication sample with a known AOSW and 
a known refractive error. These participants were classified 
as being either myopic or non-myopic based on their known 
refractive error. A receiver operating characteristics curve 
(ROC) analysis was then undertaken to determine thresh-
olds for classifying individuals as either myopic with 90% 
specificity, or as non-myopic with 90% sensitivity. Finally, 
the parameters from the logistic regression model were used 
in infer whether individuals from the discovery sample, who 
had a known AOSW but unknown refractive error, were 
myopic, non-myopic, or could not be classified.
Statistical analysis
Analyses were carried out with R (R Development Core 
Team 2008). To test for genetic variants with non-additive 
effects, the following two logistic regression models were 
fitted for the participants in the discovery sample. A separate 
model was fitted for each of the k variants:
where p̂ = ℙ(Y = 1) and Y  is the binary myopia phe-
notype, SNPk
add
 is the numeric count of minor alleles (0, 1 
or 2) for variant k carried by a participant, SNPk
domdev
 is a 
‘dominance deviation’ term equal to ‘1’ if a participant is 
heterozygous for variant k and equal to ‘0’ otherwise, and 
SNPk
cat
 is a categorical variable corresponding to the number 
of minor alleles for variant k carried by a participant coded 
as a factor with the heterozygous genotype class as the ref-
erence category (Table 1). A set of m covariates (C) are 
included, comprising of age, age squared, gender, genotyp-
ing array (UK BiLEVE Axiom array or UK Biobank Axiom 
Array) and the first 10 principal components.
Variants were classified as showing nominal evidence of 
non-additivity in the discovery sample if p < 0.05 for the 
dominance deviation regression coefficient ( 훾k ). Variants 
(1)
log
(
p̂
1 − p̂
)
∼ 훽kSNPk
add
+ 훾kSNP
k
domdev
+ 훿k
1
C1 +⋯ + 훿
k
m
Cm
(2)log
(
p̂
1 − p̂
)
∼ 휑kSNPk
cat
+ 훿k
1
C1 +⋯ + 훿
k
m
Cm
were classified as showing genotypic effects consistent with 
complete dominance or recessive action in the discovery 
sample if either the minor allele homozygote or major allele 
homozygote genotypic effects for the 휑k regression coef-
ficient had p > 0.05 in comparison with heterozygotes (in 
other words, p > 0.05 for a comparison of the trait level in 
the AA vs. AB genotype classes or p > 0.05 for a compari-
son of the trait level in the BB vs. AB genotype classes). 
Variants passing both criteria (i.e. nominal evidence of 
non-additivity and consistency with complete dominance 
or recessive effects) in the discovery sample were taken for-
ward and tested in the replication sample using the following 
linear regression model (where ŷ is the continuous refrac-
tive error phenotype and the other terms in the equation are 
defined as above):
A Bonferroni correction was applied to account for the 
number of variants tested in the replication sample.
Polygenic risk score performance with vs. 
without accounting for non‑additive effects
A series of three polygenic risk scores were calculated based 
on genotypes of the 146 variants in the 73,577 individuals 
with known refractive error in the replication sample. First, a 
‘conventional’ polygenic risk score (PRS #1) was calculated 
using the formula:
where SNPk,i
add
 is the numeric count of minor alleles (0, 1 or 
2) carried by participant i for variant k, and 훽k is the log(OR) 
for variant k for association with the AOSW-inferred binary 
myopia phenotype in the discovery sample obtained by fit-
ting Eq. 1 without a dominance deviation term.
A second polygenic risk score (PRS #2) was calculated 
using the formula:
where SNPk,i
add
 is the numeric count of minor alleles (0, 1 or 
2) carried by participant i for variant k, SNPk,i
domdev
 equals ‘1’ 
if participant i is heterozygous for variant k and equal to ‘0’ 
otherwise. 훽k and 훾k are the additive and dominance devia-
tion log(OR) coefficients for variant k, respectively, obtained 
by fitting the full Eq. 1 in the discovery sample.
A third polygenic risk score (PRS #3) was calculated 
exactly as for PRS #2 except that dominance deviation effects 
were only taken into account for 3 variants that were observed 
(3)ŷ ∼ 훽kSNPk
add
+ 훾kSNP
k
domdev
+ 훿k
1
C1 +⋯ + 훿
k
m
Cm
(4)Polygenic risk score =
N∑
k=1
훽kSNPk,i
add
(5)
Polygenic risk score =
N∑
k=1
훽kSNPk,i
add
+
N∑
k=1
훾kSNP
k,i
domdev
,
Table 1  Genotype coding for detecting non-additive effects
Term Genotype coding (A = major allele, B = minor 
allele)
AA AB BB
SNPadd 0 1 2
SNPdomdev 0 1 0
SNPcat Category 1 Reference cat-
egory
Category 2
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to show robust evidence of non-additive effects (see Results): 
ZMAT4 variant rs7829127; RD3L variant rs35337422; LAMA2 
variant rs12193446. For these 3 variants, 훽k and 훾k were taken 
as the additive and dominance deviation log(OR) coefficients 
for variant k in the discovery sample, fitted using Eq. 1. For 
the remaining 143 variants, 훾k was taken as zero, and 훽k was 
the log(OR) coefficient used in PRS #1.
The variance in refractive error explained by each poly-
genic risk score was calculated by subtracting the adjusted 
R2 of a baseline model regressing refractive error on age and 
gender from the adjusted R2 of a model regressing refrac-
tive error on age, gender and polygenic risk score. The 95% 
confidence interval of R2 was estimated by bootstrapping 
(n = 2000 bootstraps). Polygenic risk scores were calculated 
using custom scripts in R.
Simulations to assess the performance of polygenic 
risk scores if non‑additive effects are pervasive
Genotypes for 146 variants were simulated for n = 75,000 
individuals in a ‘training’ dataset and n = 75,000 individu-
als in a ‘test’ dataset, assuming allele frequencies matching 
those of the 146 genetic variants investigated above. Pheno-
types for participants were calculated assuming effect sizes 
for the 146 variants matched those observed in UK Biobank 
participants (Tedja et al. 2018), under either an additive 
model or a dominant model, such that under both models the 
set of variants together explained a fixed proportion of the 
variance in the trait (0.02 to 0.12 in steps of 0.02). A GWAS 
was performed in the training dataset to estimate effect sizes 
assuming all variants had purely additive effects, by fitting 
Eq. 3 without including a dominance deviation term. These 
effect sizes were used as weights for a polygenic risk score 
to calculate the phenotype variance explained by the 146 
variants in the test dataset, by applying Eq. 4. The above 
GWAS and PRS analyses were then repeated accounting 
for both additive and dominant effects by fitting Eq. 3 with 
a dominance deviation term and applying Eq. 5 to calcu-
late the polygenic risk score. One hundred replicates were 
performed for each condition. R code for the simulations is 
given in Supplementary Note 2.
Results
The demographic characteristics of the discovery and repli-
cation samples are summarised in Supplementary Table S1.
Testing for variants with non‑additive effects 
in the discovery sample
A total of 146 variants already known to be associ-
ated with refractive error from prior GWAS analyses 
were tested for evidence of non-additive allele-allele 
interaction (dominance) effects. Just 2 of the 146 variants 
had strong evidence of non-additive effects in the dis-
covery sample, as judged from the p-value of the domi-
nance deviation term (Eq.  2) after Bonferroni correc-
tion, p < 0.05/146 = 3.42 × 10–4. These two variants were: 
rs7829127 (ZMAT4) p = 8.42 × 10–5 and rs6420484 
(TSPAN10) p = 2.07 × 10–6. A further 13 variants showed 
nominal evidence (p < 0.05) of dominance deviation in the 
discovery sample (Table 2). Of these 15 variants, 8 also had 
genotypic effects consistent with being fully dominant or 
recessive (p > 0.05 for a comparison of the trait level in the 
AA vs. AB or p > 0.05 for a comparison of the trait level in 
the BB vs. AB genotype classes) and were taken forward for 
testing in the replication sample. (Note that TSPAN10 vari-
ant rs6420484 was not amongst the 8 variants taken forward 
since it showed evidence of incomplete dominant/recessive 
genotypic effects: AB vs. AA p = 1.95 × 10–4; AB vs. BB 
p = 7.56 × 10–20). In addition to the above analysis of vari-
ants known to be associated with refractive error, we also 
carried out a full GWAS analysis in the discovery sample to 
systematically search for variants with non-additive effects 
(Supplementary Note 3). However, no variant in the GWAS 
attained genome-wide significant evidence of a non-additive 
association with the trait (i.e. p > 5 × 10–8 for the dominance 
deviation term, for all variants; Supplementary Note 3).
Testing for variants with non‑additive effects 
in the replication sample
Of the 8 variants tested in the replication sample, only 1 
variant (rs7829127 within ZMAT4, p = 4.76 × 10–5) had 
robust independent evidence of non-additive effects, as 
gauged by a dominance deviation test with Bonferroni 
correction for 8 tests (p < 0.05/8 = 6.25 × 10–3). This vari-
ant, rs7829127, was 1 of the 2 variants with strong evi-
dence of non-additive effects in the discovery sample 
(p = 8.42 × 10–5). A further 2 of the 8 variants tested in the 
replication sample showed nominal evidence of non-addi-
tive effects: rs35337422 (RD3L) dominance deviation test 
p = 7.21 × 10–3 and rs12193446 (LAMA2) dominance devia-
tion test p = 2.57 × 10–2. That 3 of the 8 variants exhibited 
at least nominal evidence of replication was more than the 
number expected by chance (0.4 out of 8). Results for all 8 
variants are shown in Table 2 and Fig. 2.
Polygenic risk score performance with vs. 
without accounting for non‑additive effects
A ‘conventional’ polygenic risk score (PRS #1) for predict-
ing refractive error was derived using the full set of 146 
variants, under the assumption that all variants had additive 
effects. To avoid bias, the weights (SNP regression coef-
ficients) for the polygenic risk score were taken by fitting 
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Eq. 1 (but without a dominance deviation term) in the dis-
covery sample. In the replication sample of 73,577 individu-
als with known refractive error, this conventional polygenic 
risk score explained 6.01% (95% CI: 5.68 to 6.34) of the 
variance in refractive error. A second polygenic risk score 
(PRS #2) was derived, this time accounting for both the 
additive and non-additive (dominance deviation) effects of 
all 146 variants. Weights for the polygenic risk score were 
taken by fitting Eq. 1 (with a dominance deviation term) 
in the discovery sample. The variance in refractive error 
in the replication sample explained by PRS #2 was 5.92% 
(95% CI: 5.60 to 6.24), i.e. numerically slightly lower than 
that obtained using the conventional polygenic risk score, 
but with overlapping confidence intervals. A third poly-
genic risk score (PRS #3) was derived similarly, except that 
account was taken of the non-additive effects of only the 
3 variants showing robust evidence of non-additivity (the 
variants in ZMAT4, RD3L and LAMA2). PRS #3 explained 
6.04% (95% CI: 5.69 to 6.36) of the variance in refrac-
tive error in the replication sample, corresponding to an 
extremely modest relative increase in the point estimate of 
variance explained compared to the conventional PRS #1 
((6.04–6.01)/6.01 × 100 = 0.5% improvement). Once again, 
the R2 estimates for PRS #1 and PRS #3 had overlapping 
95% confidence intervals.
Simulations to assess the performance of polygenic 
risk scores if non‑additive effects are pervasive
Simulations were performed to gauge the reduction in accu-
racy of a polygenic risk score if non-additive effects were 
pervasive and yet were not accounted for. Specifically, geno-
types and phenotypes were simulated for ‘training’ and ‘test’ 
samples of 146 genetic variants in 75,000 individuals under 
either a purely additive effects model or a purely dominant 
effects model. The phenotypic variance explained (R2) by 
the variants was set at 2% to 12% in steps of 2%. Empirical 
variant effect sizes were estimated by carrying out a GWAS 
in the ‘training’ dataset, and then these effect sizes were used 
as weights for a polygenic risk score in the ‘test’ dataset. 
The results are presented in Fig. 3. When the true model 
used to generate the data was purely additive, a polygenic 
risk score that assumed an additive model performed opti-
mally, such that the observed R2 approached the simulated 
R2. In this scenario when the true model was purely additive, 
there was a small but consistent reduction in performance 
for a polygenic risk score that accounted for both additive 
and dominant effects. For example, when the true level of 
variance explained by the variants was 10%, the observed 
performance was R2 = 9.82% (95% CI 9.78% to 9.86%) for 
the additive polygenic risk score and R2 = 9.63% (95% CI 
9.59% to 9.67%) for the additive + dominant polygenic risk 
score. In contrast, when the true model was purely dominant, Ta
bl
e 
2 
 Te
sts
 fo
r n
on
-a
dd
iti
ve
 al
lel
ic 
eff
ec
ts 
in
 th
e d
isc
ov
er
y a
nd
 re
pl
ica
tio
n s
am
pl
es
Re
su
lts
 ar
e p
re
se
nt
ed
 fo
r v
ar
ian
ts 
se
lec
ted
 fo
r t
es
tin
g 
in
 th
e r
ep
lic
ati
on
 sa
m
pl
e (
i.e
. p
 <
 0.
05
 fo
r t
he
 d
om
in
an
ce
 d
ev
iat
io
n 
ter
m
 an
d 
p >
 0.
05
 fo
r e
ith
er
 th
e A
B 
vs
. A
A 
or
 A
B 
vs
. B
B 
co
m
pa
ris
on
 in
 
th
e A
OS
W
-in
fer
re
d m
yo
pi
a p
he
no
ty
pe
 in
 th
e d
isc
ov
er
y s
am
pl
e)
BA
F 
B 
all
ele
 fr
eq
ue
nc
y, 
SE
 st
an
da
rd
 er
ro
r, 
AO
SW
 ag
e-
of
-o
ns
et 
of
 sp
ec
tac
le 
we
ar
SN
P
Ge
ne
BA
F
AO
SW
-in
fer
re
d m
yo
pi
a s
tat
us
Re
fra
cti
ve
 er
ro
r
Ad
di
tiv
e e
ffe
ct
Do
m
in
an
ce
 de
vi
ati
on
Fu
ll 
do
m
. o
r r
ec
Ad
di
tiv
e e
ffe
ct
Do
m
in
an
ce
 de
vi
ati
on
Be
ta
SE
P 
va
lu
e
Be
ta
SE
p v
alu
e
AB
_A
A
p v
alu
e
AB
_B
B
p v
alu
e
Be
ta
SE
p v
alu
e
Be
ta
SE
p v
alu
e
rs7
82
91
27
ZM
AT
4
(G
) 0
.20
− 
0.0
6
0.0
1
4.6
1E
−0
6
0.1
3
0.0
3
8.4
2E
−0
5
3.9
9E
−2
8
9.2
0E
−0
1
0.0
6
0.0
2
9.5
9E
−0
3
− 
0.2
4
0.0
6
4.7
6E
 −
05
rs5
58
85
22
2
SN
TB
1
(A
) 0
.39
0.0
6
0.0
1
2.4
5E
−1
1
0.0
7
0.0
2
2.6
0E
−0
3
6.0
9E
−0
2
4.0
5E
−0
8
− 
0.0
6
0.0
2
2.0
9E
−0
4
− 
0.0
4
0.0
4
3.0
6E
−0
1
rs3
53
37
42
2
RD
3L
(C
) 0
.14
0.0
6
0.0
2
6.5
4E
−0
4
0.1
2
0.0
4
5.3
4E
−0
3
7.7
3E
−0
1
1.2
6E
−0
3
− 
0.1
3
0.0
3
9.2
8E
−0
5
− 
0.2
1
0.0
8
7.2
1E
−0
3
rs1
21
93
44
6
LA
M
A2
(G
) 0
.09
− 
0.1
6
0.0
3
3.5
7E
−0
8
0.1
6
0.0
6
1.0
3E
−0
2
2.6
5E
−6
2
1.8
8E
−0
1
0.3
3
0.0
5
6.3
5E
−1
1
− 
0.2
5
0.1
1
2.5
7E
−0
2
rs7
62
40
84
ZB
TB
38
(C
) 0
.45
− 
0.0
3
0.0
1
2.9
6E
−0
4
0.0
5
0.0
2
2.7
5E
−0
2
2.3
4E
−0
5
7.7
9E
−0
1
0.1
0
0.0
1
4.0
3E
−1
3
0.0
2
0.0
4
6.1
5E
−0
1
rs1
73
82
98
1
C
YP
26
A1
(T
) 0
.42
0.0
2
0.0
1
2.4
6E
−0
2
− 
0.0
5
0.0
2
2.8
6E
−0
2
6.0
4E
−0
4
6.6
4 E
−0
1
− 
0.0
6
0.0
1
6.0
1 E
−0
5
− 
0.0
1
0.0
4
7.0
5E
−0
1
rs1
96
90
91
TM
C
3
(A
) 0
.29
− 
0.0
2
0.0
1
2.3
6 E
−0
2
0.0
5
0.0
3
3.5
2 E
−0
2
9.9
3 E
−0
6
8.0
9 E
−0
1
0.1
0
0.0
2
1.1
1 E
−0
7
0.0
8
0.0
5
8.7
8E
−0
2
rs1
11
01
26
3
FR
M
PD
2
(T
) 0
.27
0.0
6
0.0
1
3.6
1 E
−0
8
− 
0.0
5
0.0
3
4.6
9 E
−0
2
5.9
4 E
−1
4
1.4
8 E
−0
1
− 
0.1
1
0.0
2
1.7
6 E
−0
9
− 
0.1
0
0.0
5
5.2
3E
−0
2
Molecular Genetics and Genomics 
1 3
then a polygenic risk score that assumed an additive model 
performed poorly compared to a polygenic risk score that 
accounted for dominance effects. For example, when the true 
level of variance explained by the variants was 10%, the 
observed performance was R2 = 8.14% (95% CI 8.10% to 
8.17%) for the additive polygenic risk score and R2 = 9.57% 
(95% CI 9.53% to 9.61%) for the additive + dominant poly-
genic risk score. This corresponded to a reduction in accu-
racy of 14.9% caused by ignoring dominance effects (i.e. 
reduction in accuracy = [9.57 − 8.14]/9.57 = 14.9%). On 
average across all simulations, the reduction in accuracy 
caused by ignoring dominance effects was 14%.
Discussion
Reproducible evidence of non-additive allele-allele interac-
tion effects was observed for 3 of 146 variants known to 
be associated with refractive error (rs7829127, rs35337422 
and rs12193446). By design, the pattern of allelic interac-
tion was consistent with either fully dominant or recessive 
effects.
There was compelling evidence that rs7829127 had domi-
nant/recessive effects on refractive error (since the associa-
tion withstood a correction for multiple testing in both the 
discovery and replication samples). The variant occurs in 
the first intron of the ZMAT4 gene. ZMAT4 codes for ‘zinc 
finger matrin-type 4’, a gene of unknown function expressed 
predominantly in brain tissues. In GTEx tissue samples, 
rs7829127 was identified as an eQTL for ZMAT4 expression 
Fig. 2  Genotypic effects in the discovery and replication samples 
for the eight variants with at least nominal evidence of non-additive 
allele-allele interaction effects in the discovery sample. Error bars 
represent 95% confidence interval. Grey symbols denote the effect 
expected in heterozygotes based on an additive model of SNP effects. 
The phenotype tested in the discovery sample was AOSW-inferred 
myopia status (lower panels), while the phenotype tested in the rep-
lication sample was autorefraction-measured refractive error (upper 
panels). The B allele is the minor allele
Fig. 3  Reduction in accuracy of a 146-variant polygenic risk score if 
non-additive effects are pervasive. Genotypes for 146 variants were 
simulated in ‘training’ and ‘test’ samples of 75,000 individuals. Phe-
notypes were simulated assuming all variants acted additively or 
dominantly (labelled as ‘Simulation additive’ and ‘Simulation domi-
nant’). Empirical variant effect sizes were estimated in the ‘training’ 
dataset, and then used as weights for a polygenic risk score in the 
‘test’ dataset. Polygenic risk scores were calculated assuming vari-
ants acted additively (labelled ‘Test additive’) or accounting for domi-
nance effects (labelled ‘Test additive + dominant’). The phenotypic 
variance explained by the 146 variants was varied from 0.02 to 0.12 
in steps of 0.02. Error bars represent 95% confidence intervals from 
100 replicates
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in spleen (normalised effect size = − 0.50, p = 5.70 × 10–6, 
n = 146 samples from GTEx), yet this was not the case in 
GTEx brain samples. The second variant identified as likely 
having dominant/recessive effects, rs35337422, is a mis-
sense variant that introduces an Ile → Arg substitution in 
the RD3L gene, which codes for ‘retinal degeneration 3 like’. 
The variant is classed as deleterious by SIFT, probably dam-
aging by PolyPhen, but likely benign by CADD. The effect 
of rs35337422 on RD3L gene expression level was not eval-
uated in GTEx, however variant rs8009349 is an eQTL for 
RD3L in heart tissue and is in partial LD with rs35337422 
(D′ = 1.0, r2 = 0.10). As well as being situated within RD3L, 
rs35337422 also lies within an intron of the overlapping 
TDRD9 gene (encoding ‘tudor domain containing 9’), which 
is implicated in male infertility. The third variant with evi-
dence of dominant/recessive effects, rs12193446, lies within 
an intron towards of the 5′ end of the long LAMA2 gene (as 
well as within an intron of the overlapping LOC102723409 
gene, about which little is known). The variant is not asso-
ciated with effects on gene expression in GTEx samples, 
however, it occurs in a consensus sequence for transcrip-
tion factor binding and, therefore, could potentially have a 
regulatory role in specific tissues. LAMA2 encodes the alpha 
2 chain of the laminin 2 protein, a component of basement 
membranes. Mutations in LAMA2 are a common cause of 
childhood-onset muscular dystrophy, with or without occipi-
tal cortex dysgenesis (Ding et al. 2016). Of note, all 3 of the 
variants highlighted in the current work occur within genes 
rather than the inter-genic location typical of GWAS hits. 
Making the link between a GWAS hit and the gene through 
which it exerts its phenotypic effects is a major challenge in 
genomics. Hence, the current approach of testing for non-
additive effects provides further evidence, albeit circumstan-
tial, linking the above 3 variants to specific genes likely to 
have causal roles in myopia: ZMAT4, RD3L and LAMA2.
Differentiating a dominant from a recessive effect for a 
variant influencing a quantitative trait is not possible in the 
absence of functional molecular information. For example, 
purely from the genotype–phenotype information in Fig. 2, 
it is not clear if the minor allele (C) of rs35337422 is a domi-
nant variant associated with an approximately + 0.25 D shift 
towards hyperopia or a recessive variant associated with an 
approximately − 0.25 D shift towards myopia. However, the 
functional data implicating the minor allele of rs35337422 
as a deleterious missense variant for RD3L, makes a reces-
sive effect shifting refractive error towards myopia the more 
likely option.
Variant rs6420484 was noteworthy in that there was 
strong evidence suggesting a non-additive association 
with AOSW in the discovery sample (dominance deviation 
p = 2.07 × 10–6), but no such evidence for non-additive effects 
on refractive error in the replication sample (p = 0.93). The 
minor allele of rs6420484 is a missense variant in TSPAN10 
(and is in perfect LD with deletion variant rs397693108, 
which is predicted to cause a frameshift in TSPAN10). In 
analyses using the same UK Biobank samples we studied 
here, our research group recently reported (Plotnikov et al. 
2019) that the rs6420484/rs397693108 risk alleles are asso-
ciated with an approximately 40–85% increased likelihood 
of strabismus and amblyopia, and that the variant appears 
to act recessively (recessive model vs. additive model, 
p = 8.10 × 10−05). Strabismus and amblyopia often co-occur 
with anisometropia and hyperopia in early childhood. Spec-
tacles are commonly prescribed to young children to treat 
or manage strabismus, amblyopia and anisometropia, which 
would explain why we observed evidence for a non-additive 
association between rs6420484 and AOSW in the discovery 
sample here. However, as we previously reported (Plotnikov 
et al. 2019), the relationship between rs6420484 and refrac-
tive error is more consistent with an additive than a domi-
nant or recessive mode of action, which would explain why 
we did not observe evidence for a non-additive association 
between refractive error and rs6420484 in the replication 
sample. Thus, as argued previously (Plotnikov et al. 2019), 
the causal variant at the TSPAN10 locus appears to have a 
complex and somewhat paradoxical role in eye development, 
acting with a recessive mode of action as a major risk fac-
tor for strabismus and amblyopia—which often co-occurs 
with hyperopia—while also acting with an additive mode 
of action as a minor risk factor for a more myopic refractive 
error.
One of our primary aims when embarking on this study 
was to gauge the extent to which non-additive effects might 
impair the accuracy of polygenic risk scores for refractive 
error. Simulations mimicking the worst-case-scenario in 
which all variants actually acted dominantly, demonstrated 
that a ‘conventional’ polygenic risk score that assumed vari-
ants acted additively explained ~ 14% less of the phenotype 
variance compared to a polygenic risk score that accounted 
for both additive and dominance effects (Fig. 3). However, 
only 15 of 146 of the variants examined here displayed 
nominal evidence of non-additive effects in the discovery 
sample, and only 3 of 146 had evidence of non-additive 
effects in both the discovery and replication samples. Tak-
ing our findings at face value (see below), variants with non-
additive effects on refractive error appeared to be scarce and 
our results suggested that the accuracy of a polygenic risk 
score for myopia is unlikely to suffer appreciably from not 
accounting for variants with dominant or recessive alleles 
(for example, the difference in performance was R2 = 6.04% 
vs. 6.01% when account was vs. was not taken of non-addi-
tive effects of variants in ZMAT4, RD3L and LAMA2). It 
should be stressed that the reason we detected so few vari-
ants with non-additive effects could relate to the capacity 
of additive models to adequately explain most of the vari-
ance of variants with dominant or recessive effects (Huang 
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and Mackay 2016). As we were unable to robustly identify 
additional variants with non-additive allelic effects—despite 
having access to a sample of 73,577 carefully phenotyped 
individuals—our work suggests that the use of an additive 
model to derive polygenic risk scores will provide a very 
good approximation of the results even for variants with non-
additive allelic effects. We note that the analyses we describe 
here only considered non-additive allelic effects. There is 
already very strong evidence that non-additive effects acting 
via either gene–gene or gene–environment interactions have 
profound effects on refractive error (Pozarickij et al. 2019); 
such effects would be expected to markedly impair the accu-
racy of polygenic risk scores for refractive error and myopia.
In summary, a set of 146 genetic variants known to be 
associated with refractive error were examined for non-
additive allelic effects in a total sample of 302,000 par-
ticipants from UK Biobank. Only one variant had strong 
evidence of dominant or recessive effects: rs7829127 
(p = 4.76 × 10–5) situated within the first intron of ZMAT4. 
rs7829127, or a variant in high LD, is known to act as an 
eQTL for ZMAT4 expression in a tissue-specific manner. 
Suggestive evidence also implicated another two variants 
at distinct loci: rs35337422, a missense variant in RD3L 
(p = 7.21 × 10–3), and rs12193446, an intronic variant in 
LAMA2 (p = 2.57 × 10–2). Accounting for non-additive 
effects had negligible impact on the accuracy of a poly-
genic risk score for refractive error derived using genome-
wide significant GWAS variants.
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